Finoriq research workspace

Vaxcyte, Inc. (PCVX) Institutional Holdings & 13F Ownership

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel. Review PCVX institutional holders, 13F ownership, and position changes on Finoriq.

Company Snapshot

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Company

Vaxcyte, Inc. (PCVX)

Ticker

PCVX

Market Cap

$8B

Latest Price

$55.45

Industry

Biotech & Pharma

Open insider transactions

Vaxcyte, Inc. (PCVX) Top Institutional Holders

Top current 13F holders indexed for Vaxcyte, Inc. (PCVX). Latest period 2026-03-31.

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.